| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 18/06/2024 | 22:09 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AKLI | Akili Inc |
| 18/06/2024 | 22:01 | Business Wire | Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game | NASDAQ:AKLI | Akili Inc |
| 03/06/2024 | 23:21 | Edgar (US Regulatory) | Form SC TO-T - Tender offer statement by Third Party | NASDAQ:AKLI | Akili Inc |
| 29/05/2024 | 23:32 | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NASDAQ:AKLI | Akili Inc |
| 29/05/2024 | 22:05 | Edgar (US Regulatory) | Form SC14D9C - Written communication relating to third party tender offer | NASDAQ:AKLI | Akili Inc |
| 29/05/2024 | 14:00 | Business Wire | Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company | NASDAQ:AKLI | Akili Inc |
| 14/05/2024 | 22:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AKLI | Akili Inc |
| 14/05/2024 | 22:01 | Business Wire | Akili Reports First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:AKLI | Akili Inc |
| 06/05/2024 | 23:32 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AKLI | Akili Inc |
| 30/04/2024 | 14:00 | Business Wire | Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results | NASDAQ:AKLI | Akili Inc |
| 06/03/2024 | 22:28 | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:AKLI | Akili Inc |
| 06/03/2024 | 22:11 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:AKLI | Akili Inc |
| 06/03/2024 | 22:07 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:AKLI | Akili Inc |
| 29/02/2024 | 22:01 | Business Wire | Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | NASDAQ:AKLI | Akili Inc |
| 27/02/2024 | 08:00 | Business Wire | PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan | NASDAQ:AKLI | Akili Inc |
| 26/02/2024 | 14:47 | Business Wire | Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan | NASDAQ:AKLI | Akili Inc |
| 23/02/2024 | 23:28 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:AKLI | Akili Inc |
| 23/02/2024 | 13:57 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:AKLI | Akili Inc |
| 21/02/2024 | 22:05 | Business Wire | Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates | NASDAQ:AKLI | Akili Inc |
| 18/12/2023 | 14:00 | Business Wire | EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17 | NASDAQ:AKLI | Akili Inc |
| 09/11/2023 | 22:02 | Business Wire | Akili Reports Third Quarter 2023 Financial Results and Provides Business Update | NASDAQ:AKLI | Akili Inc |
| 19/10/2023 | 18:27 | Business Wire | Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET | NASDAQ:AKLI | Akili Inc |
| 12/10/2023 | 14:00 | Business Wire | Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds | NASDAQ:AKLI | Akili Inc |
| 06/10/2023 | 13:00 | Business Wire | Akili Announces Leadership Transition | NASDAQ:AKLI | Akili Inc |
| 27/09/2023 | 13:45 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:AKLI | Akili Inc |
| 21/09/2023 | 14:00 | Business Wire | Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD | NASDAQ:AKLI | Akili Inc |
| 13/09/2023 | 14:11 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:AKLI | Akili Inc |
| 13/09/2023 | 14:00 | Business Wire | Akili Announces Business Transformation, Focusing on Non-prescription Model | NASDAQ:AKLI | Akili Inc |
| 10/08/2023 | 22:01 | Business Wire | Akili Reports Second Quarter 2023 Financial Results and Provides Business Update | NASDAQ:AKLI | Akili Inc |
| 10/07/2023 | 13:00 | Business Wire | Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET | NASDAQ:AKLI | Akili Inc |